sildenafil vs Udenafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline
sildenafil · Revatio
Marketed by Viatris and partners
NCT00644605 · Phase 3 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2028 · NCT07824674 (registry estimate)
Reported efficacy
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test). (Week 12): The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). (met)
Result source: NCT00644605
Udenafil · Zydena
Marketed by Dong-A ST and partners
NCT02304198 · Phase 2/3 · completed
The study was an open-label, single-group continuation of the randomized DA8159_PAH_II trial, with 59 participants and no concurrent placebo or active comparator. Its registered primary outcome on ClinicalTrials.gov is "Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Udenafil: no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
sildenafil
show 2 more results
show 18 more results
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 51 further endpoints in the CSV export.
Available safety results
sildenafil
| Dropout rate | — NCT00159861 · Phase 3 show 17 more results2.6%High Dose NCT00159913 · Phase 3 4.8%Low Dose NCT00159913 · Phase 3 0%Medium Dose NCT00159913 · Phase 3 52.2%high dose NCT00159874 · Phase 3 46.2%low dose NCT00159874 · Phase 3 42.1%medium dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 55.8%high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 47.6%low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 54.5%medium dose NCT00159874 · Phase 3 14% NCT00323297 · Phase 4 50% NCT01642407 · Phase 4 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00454207 · Phase 3 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | — NCT00159861 · Phase 3 show 17 more results1.3%High Dose NCT00159913 · Phase 3 2.4%Low Dose NCT00159913 · Phase 3 0%Medium Dose NCT00159913 · Phase 3 8.7%high dose NCT00159874 · Phase 3 7.7%low dose NCT00159874 · Phase 3 5.3%medium dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 6.5%high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 4.8%low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 3.6%medium dose NCT00159874 · Phase 3 4% NCT00323297 · Phase 4 — NCT01642407 · Phase 4 · registry result, not featured evidence —400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination —200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination — NCT00454207 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 77.6% NCT00159861 · Phase 3 show 17 more results—High Dose NCT00159913 · Phase 3 —Low Dose NCT00159913 · Phase 3 —Medium Dose NCT00159913 · Phase 3 —high dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 48%high dose NCT00159874 · Phase 3 —high dose NCT00159874 · Phase 3 25.5%low dose NCT00159874 · Phase 3 —low dose NCT00159874 · Phase 3 50%medium dose NCT00159874 · Phase 3 —medium dose NCT00159874 · Phase 3 44% NCT00323297 · Phase 4 0% NCT01642407 · Phase 4 · registry result, not featured evidence 5.6%400 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 10.5%200 mg/Day NCT01392469 · Phase 3 · registry result, not featured evidence · combination 15.9% NCT00454207 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | headache 67.9% (placebo 18.8%) diarrhoea 47.8% (placebo 31.3%) nausea 47% (placebo 25%) NCT00159861 · Phase 3 show 11 more resultsHigh Dose headache 15.6% (placebo 13.3%) vomiting 14.3% (placebo 6.7%) pyrexia 10.4% (placebo 1.7%) NCT00159913 · Phase 3 Low Dose headache 11.9% (placebo 13.3%) upper respiratory tract infection 9.5% (placebo 6.7%) nasopharyngitis 7.1% (placebo 6.7%) NCT00159913 · Phase 3 Medium Dose pyrexia 14.5% (placebo 1.7%) upper respiratory tract infection 14.5% (placebo 6.7%) headache 10.9% (placebo 13.3%) NCT00159913 · Phase 3 medium dose upper respiratory tract infection 29.7% headache 24.3% bronchitis 21.6% NCT00159874 · Phase 3 diarrhoea 14% (placebo 9.4%) headache 14% (placebo 13.2%) oedema peripheral 14% (placebo 15.1%) NCT00323297 · Phase 4 bronchitis 50% nasopharyngitis 50% upper respiratory tract infection 50% NCT01642407 · Phase 4 · registry result, not featured evidence 400 mg/Day vomiting 22.2% anaemia 16.7% blood potassium decreased 16.7% NCT01392469 · Phase 3 · registry result, not featured evidence · combination 200 mg/Day diarrhoea 26.3% nausea 21.1% back pain 10.5% NCT01392469 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 38.6% headache 25% flushing 22.7% NCT00454207 · Phase 3 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: sildenafil's landscape · Udenafil's landscape